HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Kitov Pharma Ltd (KTOV)
0.93  0.0299  (3.32%) 07-03 15:14
Open: 1.01 High: 1.04
Pre.close: 0.9001 Low: 0.9181
Volume: 48,964,706 Ave vol: 30,764,520
52w High: 1.44 52w Low: 0.22
MA(50): 0.632 MA(200): 0.572
EPS: -0.302 P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kitovpharma.com
Market Cap (M): 162
Shares Out (M): 175
Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. The company operates through two segments, Pain and Hypertension; and Oncology. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is Consensi a combination of APIs celecoxib and amlodipine besylate. It is also developing NT219, a small molecule that targets two oncology-related proteins to overcome resistance to cancer drug treatment. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd was founded in 2010 and is headquartered in Tel Aviv, Israel.
Technical analysis
Overall: Underperform
MA: Bullish MACD: Bullish
KDJ: Bearish RSI: Bullish
Target 1: 1.23 Target 2: 1.68
Resist 1: 1.05 Resist 2: 1.44
Support 1: 0.42 Support 2: 0.35
Company key metrics
Revenue per Share: 0.0516
Net Income per Share: 0
Cash per Share: 0.2264
Book Value per Share: 0
Price to Sales: 14.5256
Price to Book Value: 0
Earnings Yield: 0
Dividend Yield: 0
Debt to Equity: 0
Debt to Assets: 1
Financial analysis
Price to Book Value: Neutral
Return on Assets: Neutral
Return on Equity: Neutral
Discounted cash flow: Neutral
Price to Earnings: Neutral
Debt to Equity: Neutral
Stock Charts
Headline news
Thu, 02 Jul 2020
Kitov Pharma Issues CEO Shareholder Letter Providing Business Update - GlobeNewswire

Thu, 25 Jun 2020
Kitov Closes $35.0 Million Registered Direct Offering Nasdaq:KTOV - GlobeNewswire

Tue, 23 Jun 2020
Kitov Announces $35.0 Million Registered Direct Offering Nasdaq:KTOV - GlobeNewswire

Wed, 24 Jun 2020
Kitov Pharma raises $35m from institutional investors - Globes

Mon, 29 Jun 2020
-7.94% fall drives Kitov Pharma Ltd (KTOV) into becoming a interest-loosing stock for investors - Marketing Sentinel

Tue, 23 Jun 2020
Kitov Pharma +49% on collaboration with Bristol Myers in lung cancer - Seeking Alpha

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.